Product Pipeline
Adamis' (ADMP) lead product is the Symjepi pre-filled syringe injector that contains epinephrine for its use in the treatment of acute allergic reactions, including anaphylaxis, a serious life-threatening allergic reaction. Adamis offers a high dose 0.30mg variant for patients weighing 66 lbs. or more and a low dose 0.15mg variant for patients weighing between 33-66 lbs.
The Symjepi 0.3mg (low dose) injector received FDA Phase III approval in 2017 and is currently awaiting commercial launch in the U.S. which will be at the direction of Sandoz, Novartis' (NVS) generic